Results for Pembrolizumab Plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer

Rita Nanda, MD, assistant professor of Medicine, assistant director, Breast Medical Oncology, discusses results from I-SPY 2, which explored pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer.